Abstract
Background Advanced age and poor brain health have been associated with higher risk for more severe clinical and cognitive outcomes following stroke, but more accurate models for clinical prediction are needed. Machine learning based on brain scans can be used to estimate brain age of individual patients, and the corresponding difference from chronological age, the brain age gap (BAG) has been investigated in a range of clinical conditions. Yet, the predictive value for post stroke NCD has not been established. To this end, using longitudinal data we aimed to investigate the association between BAG and post-stroke neurocognitive disorder (NCD) over time.
Methods 269 stroke survivors (55.4% women, mean (SD) age = 71 (11) years) were included from the Norwegian Cognitive Impairment After Stroke (Nor-COAST) study. MRI and clinical data were collected shortly after the acute stroke (neuropsychological data first after 3 months) and at 18- and 36 months follow-up. The brain age model was trained in an independent sample using established protocols based on machine learning and brain structural features from Freesurfer and applied to the current dataset. We used linear mixed effects (LME) models and survival analysis to assess the associations between cognitive status and longitudinal brain age.
Results LMEs revealed a main effect of BAG on post stroke NCD across time, confirming our main hypothesis that a younger appearing brain may protect against post stroke NCD. For patients with no NCD at baseline, survival analysis suggested that higher baseline BAG was associated with higher risk of post stroke NCD at 18 and 36 months.
Conclusion A younger appearing brain is associated with lower risk of post stroke NCD up to 36 months after a stroke, even among those showing no evidence of impairments 3 months after hospital admission. Brain age prediction based on brain scans provides a reliable assessment of brain structure and is sensitive to post stroke NCD with predictive value for cognitive decline among patients with no impairment at the initial assessment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by a research grant from the South-Eastern Norway Regional Health Authority (Helse Sor-Ost).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nor-COAST was approved by the regional committee for medical and health research, REK Nord (REK number: 2015/171), and registered on clinicaltrials.gov (NCT02650531). REK Nord has also approved this current sub study (REK number: 2019/397).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
